PRIMARY STUDY
Effects of the Cannabinoid-1 Receptor Antagonist/Inverse Agonist Rimonabant on Satiety Signaling in Overweight People with Schizophrenia
Key Findings: In patients with schizophrenia on a second-generation antipsychotic (SGA), food consumption was lower in the group also receiving the CB1 antagonist, rimonabant. However, there was no significant change in satiety. Rimonabant has since been removed from global markets due to significant safety concerns.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 14
Study Result: Negative
Research Location(s): United States
Year of Pub: 2013
Cannabinoids Studied: SR-x Synthetic Cannabinoids, Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Receptors Studied: CB1, CB1 agonist, CB1 antagonist
Ligands Studied: Ghrelin, Insulin, Leptin, Serotonin
Route of Administration: Oral (Ingestion)
Citation: Warren KR, et al. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2013; 33:118-20. doi: 10.1097/JCP.0b013e3182793843
Authors: Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL
